21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

24 October 2022 - Event

BIO-EUROPE 2022: FACILITATING GLOBAL PARTNERSHIPS THAT DRIVE LIFE SCIENCE DEALMAKING

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

BEAM News
Member News
Events

Latest news of BEAM Alliance

31 January 2022 - BEAM Alliance

Towards a functioning AMR market: 4 pillars for a PULL incentive in Europe

In its latest position paper, BEAM Alliance proposes 4 pillars to design an efficient PULL incentive for AMR in Europe.

25 November 2021 - BEAM Alliance

Antimicrobial Resistance Campaign 2021

Antimicrobial Resistance Campaign 2021. The needs of SMEs must be considered when reshaping the regulatory framework in AMR innovation.

24 November 2021 - BEAM Alliance

AMR: The life of innovative SMEs

WAAW 2021. We take you behind the scenes. This series of comics illustrates the life of SMEs innovating in the…

17 November 2021 - BEAM Alliance

20 research, medical and pharmaceutical organizations call on G7 to step up action against antibiotic resistance

20 national and international organisations from academia, healthcare, global health and the pharmaceutical industry appealed today to G7 governments to…

21 October 2021 - BEAM Alliance

How the EU Pharmaceutical Strategy could help prevent the next pandemic

Video recordings of BEAM’s Roundtable. Discussion with EC officials and experts on the AMR initiatives of the EU Pharmaceutical Strategy.

27 September 2021 - BEAM Alliance

BEAM Alliance wants HERA to effectively support R&D in antimicrobial resistance

BEAM Alliance welcomes the HERA proposal but urges EU Member States to recognise the importance of early-stage support for Research…

page 1/5

Tweets by alliancebeam

View twitter feed

Latest news of BEAM Members

11 August 2022 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Completes Patient Enrollment in Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis

XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics…

26 July 2022 - Destiny Pharma plc

Publication of new data on NTCD-M3 confirms potential as an effective treatment for prevention of C. difficile infections

Destiny Pharma is currently finalising preparations for the pivotal Phase 3 clinical trial of NTCD-M3 and seeking partners to help…

19 July 2022 - Destiny Pharma plc

Destiny Pharma announces positive update from US FDA on XF-73 Phase 3 development plans

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening…

18 July 2022 - Nabriva Therapeutics GmbH

Nabriva Therapeutics Expands XENLETA® (lefamulin) Presence with Exclusive Agreement with Er-Kim Pharmaceuticals

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.

12 July 2022 - Destiny Pharma plc

Destiny Pharma receives award from the Cystic Fibrosis Foundation

Destiny Pharma’s lead compound, XF-73, is being prepared for Phase 3 clinical development to prevent post-surgical Staphylococcal infections.

07 July 2022 - Destiny Pharma plc

Destiny Pharma announces publication of XF-73 drug synergy data

The addition of XF-73 significantly enhances the potency of these approved antibacterial drugs, which should improve their ability to treat…

page 1/41

Events

24 October 2022

BIO-EUROPE 2022: FACILITATING GLOBAL PARTNERSHIPS THAT DRIVE LIFE SCIENCE DEALMAKING

BIO-Europe® is the preeminent partnering conference for the life sciences, bringing together international decision makers from the biotechnology, pharmaceutical and…

15 October 2022

6th International Course on Antibiotics and Resistance (ICARe)

The emergence and spread of bacteria resistant to many drug classes seriously threaten all branches of modern medicine. There is…

30 August 2022

CDC/FDA Public Online Workshop: Drug Development Considerations for the Prevention of HealthCare-Associated Infections

The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop.

23 August 2022

REVIVE Webinar: Challenges of developing antibiotic combinations

REVIVE is a space for everybody with an interest in antimicrobial R&D.

10 August 2022

REVIVE Webinar: Animal models to study the activity of antibiotics

REVIVE is a space for everybody with an interest in antimicrobial R&D.

26 July 2022

REVIVE Webinar: New approaches to antibiotic discovery

REVIVE is a space for everybody with an interest in antimicrobial R&D.

22 June 2022

JPIAMR Innovation Online Workshop: Developing Diagnostic tools for Drug Resistant Infections for Human and Animal Health

JPIAMR, in partnership with Innovate UK KTN, are hosting this innovation workshop to provide information about the challenges in translating…

21 June 2022

JPIAMR Innovation Online Workshop: Developing Novel Antimicrobial Therapeutics

JPIAMR, in partnership with Innovate UK KTN, are hosting this innovation workshop to provide information about the challenges in translating…

08 June 2022

COMBINE Expert Workshop on Monoclonal Antibodies for AMR Pathogens

The Paul-Ehrlich-Institut, on behalf of the COMBINE project, is organising a two-day, free, virtual workshop to discuss recurring challenges and…

page 1/13